A phase III multicenter trial comparing two different sequences of second/third line therapy (irinotecan/cetuximab followed by FOLFOX-4 vs. FOLFOX-4 followed by irinotecan/cetuximab in K-RAS wt metastatic colorectal cancer (mCC) patients refractory to FOLFIRI/Bevacizumab

Gerardo Rosati, Stefano Cascinu, Sara Lonardi et al.|Annals of Oncology|2015

Cited by 2